A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
Public ClinicalTrials.gov record NCT07221149. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
ROSETTA Gastric-204: A Blinded, Randomized, Phase 2/3 Study of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The purpose of this study is to evaluate the safety and efficacy of Pumitamig in combination with chemotherapy versus Nivolumab in combination with chemotherapy in participants with previously untreated advanced or metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma
Study identification
- NCT ID
- NCT07221149
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2, Phase 3
- Enrollment
- 690 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Mar 12, 2026
- Primary completion
- Nov 7, 2030
- Completion
- Sep 10, 2032
- Last update posted
- Sep 7, 2026
2026 – 2032
United States locations
- U.S. sites
- 34
- U.S. states
- 18
- U.S. cities
- 32
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Local Institution - 0284 | Phoenix | Arizona | 85054 | Not yet recruiting |
| USC/Norris Comprehensive Cancer Center | Los Angeles | California | 90033 | Recruiting |
| University of California, Irvine (UCI) Health - UC Irvine Medical Center | Orange | California | 92868 | Recruiting |
| Local Institution - 0428 | San Francisco | California | 94158 | Not yet recruiting |
| Florida Cancer Specialists - South | Fort Myers | Florida | 33901 | Recruiting |
| Local Institution - 0433 | Jacksonville | Florida | 32224 | Not yet recruiting |
| Florida Cancer Specialists - North | St. Petersburg | Florida | 33701 | Recruiting |
| Moffitt Cancer Center | Tampa | Florida | 33612 | Recruiting |
| Emory University | Atlanta | Georgia | 30308 | Recruiting |
| Local Institution - 0379 | Chicago | Illinois | 60637 | Not yet recruiting |
| Local Institution - 0268 | Iowa City | Iowa | 52242 | Not yet recruiting |
| Local Institution - 0259 | Rochester | Minnesota | 55905 | Not yet recruiting |
| Missouri Cancer Associates | Columbia | Missouri | 65201 | Recruiting |
| Local Institution - 0286 | Omaha | Nebraska | 68198 | Not yet recruiting |
| Northwell Health/ RJ Zuckerberg Cancer Center | Lake Success | New York | 11042 | Recruiting |
| Memorial Sloan Kettering Cancer Center | New York | New York | 10065 | Recruiting |
| Local Institution - 0274 | Rochester | New York | 14642 | Not yet recruiting |
| Local Institution - 0245 | Chapel Hill | North Carolina | 27599 | Not yet recruiting |
| Local Institution - 0443 | Cleveland | Ohio | 44106 | Not yet recruiting |
| Local Institution - 0222 | Cleveland | Ohio | 44195 | Not yet recruiting |
| Oncology Associates Of Oregon, Pc | Eugene | Oregon | 97401 | Recruiting |
| Northwest Cancer Specialists, P.C. | Portland | Oregon | 97213-2982 | Recruiting |
| UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| SCRI Oncology Partners | Nashville | Tennessee | 37203 | Recruiting |
| Tennessee Oncology | Nashville | Tennessee | 37203 | Recruiting |
| Texas Oncology - Amarillo Cancer Center | Amarillo | Texas | 79124 | Recruiting |
| Texas Oncology-Austin Central | Austin | Texas | 78731 | Recruiting |
| Texas Oncology | Beaumont | Texas | 77702 | Recruiting |
| Texas Oncology - Northeast Texas | Denison | Texas | 75020 | Recruiting |
| Texas Oncology - DFW | Grapevine | Texas | 76051 | Recruiting |
| University of Texas MD Anderson Cancer Center | Houston | Texas | 77030 | Recruiting |
| Texas Oncology - San Antonio | San Antonio | Texas | 78240 | Recruiting |
| Oncology and Hematology Associates of Southwest Virginia, Inc. - Salem | Salem | Virginia | 24153 | Recruiting |
| University of Wisconsin Carbone Cancer Center - University Hospital | Madison | Wisconsin | 53792 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 127 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07221149, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Sep 7, 2026 · Synced Sep 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT07221149 live on ClinicalTrials.gov.